Melanoma-associated antigen peptide-pulsed dendritic cell vaccine

The target described refers to a specialized therapeutic strategy involving dendritic cells (DCs) engineered to trigger a potent immune response against melanoma. This approach involves loading autologous dendritic cells with melanoma-associated antigen (MAA) peptides, such as gp100, MART-1, and tyrosinase, which are presented on MHC class I molecules (specifically HLA-A2) to prime and activate CD8+ cytotoxic T lymphocytes (CTLs) (Schuler-Thurner et al., 2002, J. Exp. Med.). To ensure a sustained and effective response, the DCs are also pulsed with Keyhole Limpet Hemocyanin (KLH), a highly immunogenic carrier protein. KLH-derived peptides are presented on MHC class II molecules to activate CD4+ helper T cells, which provide essential cytokine support and help overcome the immunosuppressive tumor microenvironment (Banchereau & Palucka, 2005, Nat. Rev. Immunol.). This dual-presentation mechanism aims to generate a robust, multi-pronged attack against melanoma cells expressing these specific antigens. Clinically, this strategy is primarily utilized in personalized cancer vaccines for HLA-A2-positive patients with high-risk or metastatic melanoma (ClinicalTrials.gov, NCT00001592). The success of the therapy is often linked to the induction of antigen-specific T-cell expansion and can be associated with autoimmune side effects like vitiligo, which serves as a clinical indicator of anti-melanocyte activity.

Other names

HLA-A2-restricted melanoma peptide vaccineDC-Mel-KLH vaccineMelanoma antigen-loaded dendritic cellsAutologous dendritic cells pulsed with melanoma peptides and KLHMelanoma-associated antigen (MAA) peptide-MHC complexes

The vaccine functions by utilizing dendritic cells to present melanoma-specific peptides (e.g., gp100, MART-1, tyrosinase) via MHC class I (HLA-A2) to activate cytotoxic CD8+ T cells, while simultaneously presenting KLH-derived peptides via MHC class II to activate CD4+ helper T cells, thereby inducing a coordinated anti-tumor immune response.